GOLDFINCH BIO TO PRESENT DATA ON TRPC5 INHIBITOR FOR PROTEINURIC KIDNEY DISEASE AND ITS KIDNEY GENOME ATLAS FOR IDENTIFICATION OF NOVEL TARGETS

Five abstracts accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2018 Conference

CAMBRIDGE, Mass., October 5, 2018 – Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-informed kidney diseases, today announced that five abstracts were selected for presentation at the American Society of Nephrology (ASN) Kidney Week 2018 Conference being held October 23-28, 2018 in San Diego. The abstracts include preclinical data related to Goldfinch Bio’s lead drug development candidate,  GFB-887, a selective inhibitor of transient receptor potential canonical 5 (TRPC5), as well as data from the company’s Kidney Genome Atlas demonstrating the identification of novel pathways and targets for the treatment of kidney diseases.

“We are delighted that such a comprehensive representation of Goldfinch’s research has been selected for presentation at Kidney Week 2018 and are particularly looking forward to sharing our data about TRPC5 therapeutic mechanisms and the broad potential of our Kidney Genome Atlas,” said Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio.

Poster Presentations:
Title: Characterizing podocyte cell cultures and genetic markers of podocyte maturity
Session: Cellular Crosstalk in Glomerular Diseases - I [PO1201-1] 
Date/Time: October 25, 2018 from 10:00 AM to 12:00 PM 
Abstract #: 3016918
Poster #: TH-PO788 

Title: Kidney Genome Atlas: a whole-genome landscape of more than 2,000 kidney disease  patients 
Session: Molecular Mechanisms of CKD - II [PO1903-2] 
Date/Time: October 26, 2018 from 10:00 AM to 12:00 PM 
Abstract #: 3021496
Poster #: FR-PO840 

Title: Modeling of FSGS in podocin R138Q knock-in iPSC-derived human organoids 
Session: Genetic Diseases of the Kidneys: Non-Cystic - II [PO1002-2] 
Date/Time: October 26, 2018 from 10:00 AM to 12:00 PM 
Abstract #:   3024157
Poster #: FR-PO645 

Title: Small molecule inhibition of TRPC5 protects against podocyte injury and proteinuria in FSGS
Session: Cellular Crosstalk in Glomerular Diseases - II [PO1201-2] 
Date/Time: October 27, 2018 from 10:00 AM to 12:00 PM 
Abstract #:  3023973
Poster #: SA-PO317 

Title: Characterization of GFB-8438, a potent and selective TRPC5 inhibitor under evaluation for the treatment of FSGS
Session: Pharmacology [PO1700-1] 
Date/Time: October 27, 2018 from 10:00 AM to 12:00 PM 
Abstract #:  3024765
Poster #: SA-PO643 

About TRPC5
TRPC5 is a calcium-permeable cation channel that has been implicated in the pathogenesis of FSGS by triggering a Rac1-TRPC5 disease pathway. Recent evidence has demonstrated that TRPC5 and Rac1, a critical regulator of cellular motility, form a vicious cycle that drives pathogenic remodeling of the actin cytoskeleton in podocytes. This causes podocyte loss and breach of the filtration barrier, which leads to proteinuria, the hallmark of progressive kidney diseases such as FSGS. Inhibition of TRPC5 offers a potential point of therapeutic intervention to halt progression of FSGS to kidney failure1. TRPC5 represents a target for therapeutic intervention to halt progression of FSGS to kidney failure.

About Goldfinch Bio
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for patients with kidney diseases. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney diseases. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.

Contact:
The Yates Network
Gina Nugent 617-460-3579
gina@theyatesnetwork.com

Press ReleasesAdam Tebbe